Enhanced immuno-detection of shed extracellular domain of HER-2/neu

Sinang Chourb, Brian C. Mackness, Leslie R. Farris, Melisenda J. McDonald

.

DOI: 10.4236/health.2009.14053                

Abstract

HER-2/neu oncogene is over-expressed and amplified in patients associated with metastatic breast cancer. An increased level (>15 ng/mL) in the shed extracellular domain (sECD-HER 2/neu) is indicative of the potential presence and as-sociated progression of this disease. A fluo-rescent ELISA incorporating the newly devel-oped ALYGNSA antibody-orientation system revealed a 10-fold increase in sensitivity (≤0.63 ng/mL) of sECD-HER 2/neu when compared to a control standard ELISA kit (≤7.5 ng/mL). This enhanced mode of detection has the potential to not only address breast and other cancers per se but also permit an in depth evaluation of “shed extracellular domains”, in general, and the role of these “proteolytic derived factors” in physiological signalling at normal levels.

Keywords

HER-2/neu; Shed Extracellular Domain; C-erbB2; Breast Cancer Marker; ELISA; Fluorescent immunoassay; ALYGNSA

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Slamon,D.J., Clark, G.M., Wong, S.G., Levin,W.J., Ull-rich, A. and McGuire, W.L. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-182.
[2]	Ménard, S., Pupa, S.M., Campiglio, M. and Tagliabue, E. (2003) Biologic and therapeutic role of HER2 in cancer. Oncogene, 22, 6570-6578.
[3]	Ross, J.S., Fletcher, J.A., Linette, G.P., Stec, J., Clark, E., Ayers, M., et al. (2004) Targeted therapy in breast cancer: The HER-2/neu gene and protein. Mol. Cell. Proteomics, 3, 379-398.
[4]	Carney, W.P., Leitzel, K., Ali, S., Neumann, R. and Lip-ton, A. (2007) A HER-2/neu diagnostics in breast cancer. Breast Cancer Res., 9, 207-217.
[5]	Bramwell, V.H.C., Doig, G.S., Tuck, A.B., Wilson, S.M., Tonkin, K.S., Tomiak, A., et al. (2009) Changes over time of extracellular domain of HER2 (ECD/HER2) se-rum levels have prognostic value in metastatic breast cancer. Breast Cancer Res. Treat., 114, 503-511.
[6]	Lipton, A., Ali, S.M., Leitzel, K., Demers, L., Chinchilli, V., Engle, L., et al. (2002) Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J. Clin. Oncology, 20, 1467- 1472.
[7]	Fornier, M.N., Seidman, A.D., Schwartz, M.K. and Ghani, F. (2005) Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hy-bridization and with response rate. Ann. Oncology, 16, 234-239.
[8]	Slamon, D.J., Jones, B.L., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., et al. (2001) Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that over expresses Her2. N. Engl. J. Med., 344, 783-792.
[9]	Payne, R.C., Allard, J.W., Anderson-Mauser, L., Hum-phreys, J.D., Tenney, D.Y. and Morris, D.L. (2000) Automated assay for HER-2/neu in serum. Clin. Chem., 46, 175-182.
[10]	Meenakshi, A., Kumar, R.S. and Kumar, N.S. (2002) ELISA for quantitation of serum c-erbb-2 oncoprotein in breast cancer patients. J. Immunoassay Immunochem., 23, 293-305.
[11]	James, R., Thriveni, K., Ramaswamy, G., Krishnamoor-thy, L., Mukherjee, G., Deshmane,P.P.V., et al. (2008) Evaluation of immunohistochemistry and enzyme linked immunosorbent assay for Her-2/Neu expression in breast carcinoma. Indian J. Clin. Biochem., 23, 345-351.
[12]	Clarizia, L-J.A., Sok, D., Wei, M., Mead, J., Barry, C. and McDonald, M.J. (2009) Antibody orientation en-hanced by selective polymer–protein noncovalent inter-actions. Anal. Bioanal. Chem., 393, 1531-1538.
[13]	Sok, D., Clarizia, L-J.A., Farris, L.R. and McDonald, M.J., (2009) Novel fluoroimmunoassay for ovarian can-cer biomarker CA-125. Anal. Bioanal. Chem., 393, 1521-1523.
[14]	Mackness, B.C., Chourb, S., Farris, L.R. and McDon-ald, M.J. Polymer-protein enhanced fluoroimmunoassay for prostate-specific antigen. Anal. Bioanal. Chem., DOI 10.1007/s00216-009-3234-6.
[15]	Cho, H.S., Mason, K., Ramyar, K.X., Stanley, A.M., Gabelli, S.B., Denney, D.W., et al. (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature, 421, 756-760.
[16]	Zhang, H., Berezov, A., Wang, Q., Zhang, G., Drebin, J., Murali, R., et al. (2007) Erbb receptors: from oncogenes to targeted cancer therapies. J. Clin. Invest., 117, 2051- 2058.
[17]	Ferguson, M.K. (2008) Structure-based view of epider-mal growth factor receptor regulation. Annu. Rev. Bio-phys., 37, 353-73.
[18]	de Graeff, P., Crijns, A.P.G., ten Hoor, K.A., Klip, H.G., Hollema, H., Oien, K., et al. (2008) The erbb signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br. J. Cancer, 99, 341-349.
[19]	Osman, I., Mikhail, M., Shuch, B., Clute, M., Cheli, C.D., Ghani, F., et al. (2005) Serum levels of shed Her2/Neu protein in men with prostate cancer correlate with disease progression. J. Urology, 174, 2174-2177.
[20]	Salam, I.A. Gaballa, H.E. and Wahab, N.A. (2009) Se-rum levels of epidermal growth factor and HER-2Neu in non small-cell lung cancer: prognostic correlation. Med. Oncology, 26,161-166.
[21]	Hartwell, L., Mankoff, D., Paulovich, A., Ramsey, S. and Swisher, E. (2006) cancer biomarkers: a systems ap-proach. Nature Biotech, 24, 905-908
[22]	Jain, K.K. (2008) Innovations, challenges and future prospects of oncoproteomics. Mol. Oncology, 2, 153-160.
[23]	Yuan, C.-X., Lasut, A.L., Wynn, R., Neff, N.T., Hollis, G.F., Ramaker, M.L., et al. (2003) Purification of Her-2 extracellular domain and identification of its cleavage site. Protein Expression Purif, 29, 217-222.
[24]	Blobel, C.P. (2005) ADAMs: key components in EGFR signalling and development. Nature Rev. Mol. Cell. Biol., 6, 32-44.
[25]	Murphy, G., Murthy, A. and Khokha, R. (2007) Clipping, shedding and RIPping keep immunity on cue. Trends Immunol, 29, 75-82.